Brain Amyloid Imaging — FDA Approval of Florbetapir F18 Injection

Abstract

The Centers for Disease Control and Prevention recently estimated that more than 16 million Americans are living with cognitive impairment.¹ Cognitive impairment can be ascribed to a variety of disorders, some of which can be treated (e.g., severe depression or effects of medications) but others of which may signal the development of incurable dementias, such as Alzheimer's disease. For these reasons, the development and improvement of diagnostic procedures — and neuroimaging procedures, in particular — that aid in characterizing cognitive impairment is a health care priority. Improved diagnostic evaluation of patients with cognitive impairment may also enhance the development of therapies, since reliable diagnoses are critical to the success of clinical trials.